Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin.
Clinical trials
HFpEF
Heart failure
Preserved ejection fraction
Therapies
Journal
Heart failure reviews
ISSN: 1573-7322
Titre abrégé: Heart Fail Rev
Pays: United States
ID NLM: 9612481
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
accepted:
07
03
2022
pubmed:
30
4
2022
medline:
9
2
2023
entrez:
29
4
2022
Statut:
ppublish
Résumé
Heart failure with preserved ejection fraction (HFpEF) is a highly prevalent syndrome with multifaceted pathophysiology. All approaches to neurohormonal modulation were shown not to improve survival in HFpEF, despite their well-established efficacy in heart failure with reduced ejection fraction (HFrEF). This might be attributed to suboptimal study design, inadequate diagnostic criteria, or statistical power, but is also likely to reflect a lack of consideration for its clinical heterogeneity. The attention then shifted to the phenotypic heterogeneity of HFpEF, with the ultimate goal of developing therapies tailored to individual patient phenotypes. Recently, the sodium-glucose co-transporter-2 inhibitor (SGLT2i) empagliflozin has been found to reduce the combined risk of cardiovascular death or hospitalization for HF in patients with HFpEF, a result driven by a reduction in HF hospitalizations. This paper recapitulates the journey from the failure of trials on neurohormonal antagonists to the attempts of personalized approaches and the new perspectives of SGLT2i therapy for HFpEF.
Identifiants
pubmed: 35488030
doi: 10.1007/s10741-022-10228-8
pii: 10.1007/s10741-022-10228-8
pmc: PMC9902425
doi:
Substances chimiques
empagliflozin
HDC1R2M35U
Benzhydryl Compounds
0
Glucosides
0
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
179-191Informations de copyright
© 2022. The Author(s).
Références
JAMA. 2016 Jan 5;315(1):36-46
pubmed: 26746456
Cell Physiol Biochem. 2017;41(6):2503-2512
pubmed: 28472796
Circ Heart Fail. 2016 Apr;9(4):e002729
pubmed: 27072860
Medicines (Basel). 2020 May 20;7(5):
pubmed: 32443705
J Am Coll Cardiol. 2021 Apr 6;77(13):1660-1669
pubmed: 33637354
Circulation. 2021 Oct 19;144(16):1284-1294
pubmed: 34459213
J Am Coll Cardiol. 2020 Aug 4;76(5):503-514
pubmed: 32731928
Circulation. 2015 Feb 10;131(6):550-9
pubmed: 25552356
J Mol Cell Cardiol. 2008 Jul;45(1):32-43
pubmed: 18439620
J Clin Med. 2021 Jun 26;10(13):
pubmed: 34206864
Am J Physiol Heart Circ Physiol. 2014 May;306(9):H1364-70
pubmed: 24658015
ESC Heart Fail. 2021 Aug;8(4):3248-3256
pubmed: 34076960
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Diabetes Obes Metab. 2015 Dec;17(12):1180-93
pubmed: 26343814
N Engl J Med. 2014 Apr 10;370(15):1383-92
pubmed: 24716680
Eur Heart J. 2006 Mar;27(5):562-8
pubmed: 16443607
Circulation. 2011 Jul 12;124(2):164-74
pubmed: 21709061
Cardiovasc Res. 2019 Feb 1;115(2):266-276
pubmed: 30475996
Circulation. 2006 Aug 8;114(6):597-605
pubmed: 16894049
J Am Heart Assoc. 2015 Oct 12;4(10):e002137
pubmed: 26459931
J Am Coll Cardiol. 2009 Mar 31;53(13):1119-26
pubmed: 19324256
Lancet. 2012 Oct 20;380(9851):1387-95
pubmed: 22932717
JACC Heart Fail. 2016 Feb;4(2):140-149
pubmed: 26682793
Circulation. 2021 Oct 12;144(15):1193-1195
pubmed: 34459212
Wien Klin Wochenschr. 2016 Dec;128(23-24):882-889
pubmed: 27590259
World J Cardiol. 2015 Sep 26;7(9):544-54
pubmed: 26413231
Circulation. 2016 Aug 9;134(6):435-7
pubmed: 27502906
Eur Heart J. 2005 Feb;26(3):215-25
pubmed: 15642700
N Engl J Med. 2019 Oct 24;381(17):1609-1620
pubmed: 31475794
Pharmacol Res. 2020 Aug;158:104870
pubmed: 32434052
Circulation. 2015 Jan 20;131(3):269-79
pubmed: 25398313
JACC Heart Fail. 2013 Apr;1(2):115-22
pubmed: 24621836
J Am Coll Cardiol. 2017 Aug 8;70(6):776-803
pubmed: 28461007
JAMA. 2014 Nov 19;312(19):2008-18
pubmed: 25399276
Circulation. 2015 Jan 6;131(1):34-42
pubmed: 25406305
Eur Heart J. 2006 Oct;27(19):2338-45
pubmed: 16963472
N Engl J Med. 2021 Oct 14;385(16):1531-1533
pubmed: 34449179
Lancet. 2020 Sep 19;396(10254):819-829
pubmed: 32877652
Eur Respir Rev. 2019 Oct 1;28(153):
pubmed: 31578210
P T. 2015 Jun;40(6):364-8
pubmed: 26045645
Diabetologia. 2017 Mar;60(3):568-573
pubmed: 27752710
Curr Heart Fail Rep. 2017 Jun;14(3):197-202
pubmed: 28434088
Heart. 2020 Mar;106(5):342-349
pubmed: 31911501
JAMA. 2019 Jun 4;321(21):2101-2112
pubmed: 31162568
Diab Vasc Dis Res. 2016 Mar;13(2):119-26
pubmed: 26873905
Nat Med. 2021 Aug;27(8):1477-1482
pubmed: 34385704
JACC Heart Fail. 2020 Mar;8(3):172-184
pubmed: 31926856
Adv Ther. 2019 Oct;36(10):2769-2782
pubmed: 31444706
Circ Heart Fail. 2015 Jan;8(1):33-40
pubmed: 25399909
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Heart Lung Circ. 2017 May;26(5):433-441
pubmed: 27816421
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Am Heart J. 2015 Mar;169(3):323-33
pubmed: 25728721
Nat Med. 2021 Nov;27(11):1954-1960
pubmed: 34711976
Eur J Heart Fail. 2020 Jan;22(1):148-158
pubmed: 31637815
Circ Heart Fail. 2010 Jan;3(1):29-34
pubmed: 19917649
J Card Fail. 2005 Apr;11(3):191-5
pubmed: 15812746
Circ J. 2012;76(4):833-42
pubmed: 22451450
JAMA. 2020 Oct 20;324(15):1512-1521
pubmed: 33079152
JAMA. 2018 Nov 6;320(17):1764-1773
pubmed: 30398602
N Engl J Med. 2008 Dec 4;359(23):2456-67
pubmed: 19001508
Cardiovasc Diabetol. 2017 May 11;16(1):63
pubmed: 28490337
Circ Heart Fail. 2017 Jul;10(7):
pubmed: 28705911
Lancet. 2003 Sep 6;362(9386):777-81
pubmed: 13678871
Circ Heart Fail. 2013 Mar;6(2):254-63
pubmed: 23258574
Circulation. 2020 Feb 4;141(5):338-351
pubmed: 31736337
JAMA. 2013 Feb 27;309(8):781-91
pubmed: 23443441
Circulation. 2020 Sep 15;142(11):1028-1039
pubmed: 32410463
J Hum Hypertens. 2019 Apr;33(4):327-339
pubmed: 30443007
Acta Cardiol. 2022 Apr;77(2):97-104
pubmed: 33653227
Prog Cardiovasc Dis. 2021 Jul-Aug;67:89-97
pubmed: 33839166